Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.